

<b>Name</b>	Sung-Soo Park, MD, PhD
<b>Current Position &amp; Affiliation</b>	Associate professor, Division of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea.
<b>Country</b>	Seoul St. Mary's Hospital 222 Banpo-daero, Seocho-gu, Seoul 06591, South Korea
<b>Major Field</b>	Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

#### **Educational Background**

February, 2008	Achievement of Bachelor degree The Catholic university of Korea, Seoul, Korea
August, 2017	Achievement of Master's degree The Catholic university of Korea, Seoul, Korea
August, 2020	Achievement of Doctor's degree The Catholic university of Korea, Seoul, Korea

#### **Professional Experience**

18. Feb, 2008	Acquisition of medical (doctoral) license (No. 95674)
Mar 2008 – Feb 2009	Internship
Mar 2009 – Apr 2012	Navy Doctor, Lieutenant, Republic of Korean Navy
May 2012 – Feb 2016	Resident of internal medicine, Catholic medical center, The Catholic University of Korea
Mar 2016 – Feb 2018	Fellowship, Division of Hematology, Department of Internal Medicine, Seoul St Mary's hospital, College of Medicine, The Catholic university of Korea
Mar 2018 – Feb 2023	Assistant professor, Division of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea.
March 2023 –	Associate professor, Division of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea.

---

**Other Experience and Professional Memberships**

---

1. Korean Society of Hematology
  2. Korean Society of Hematopoietic Stem Cell Transplantation
  3. Korean Society of Internal Medicine
  4. International Society For Cell & Gene therapy
  5. Asian Myeloma Network
- 

**Main Scientific Publications**

---

1. Choi S, **Park SS**, Lee CH, et al. Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study. *Blood Cancer J.* 2025;15(1):185.
  2. Ko H, Choi S, **Park SS**, Jung S, Lee CH, Han S, Min CK. Quantitative risk of underlying disease conditions for progression from monoclonal gammopathy to multiple myeloma: a nationwide cohort study. *ESMO Open.* 2025 Jul;10(7):105327.
  3. **Park SS**, Kim ES, Youn JC, Jung MH, Park J, Nam KE, Min CK, Armenian SH, Lee K. Risk Stratification Strategies and Implementation of Exercise Training in Patients with Multiple Myeloma. *Curr Oncol Rep.* 2025 Nov 3.
  4. Ha J, Choi S, **Park SS**, Moon S, Han J, Lee J, Baek KH, Han S, Min CK. Fractures incidence and its association on mortality in multiple myeloma patients: a nationwide cohort study (CAREMM-2105 study). *Sci Rep.* 2025 Jul 27;15(1):27321.
  5. **Park SS**, Choi S, Jung S, et al. Cost-Effectiveness Analysis of Daratumumab Monotherapy and Subsequent Therapies in Heavily Treated Relapsed/Refractory Multiple Myeloma: A Feasible Methodology using a Korean Nationwide Population Cohort. *Cancer Res Treat.* Published online April 15, 2025.
  6. Oh S, **Park SS**, Lee JY, et al. Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study. *Blood Res.* 2025;60(1):54.
  7. **Park SS**, Kim NY, Lim JY, et al. Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases. *Ann Lab Med.* 2025;45(3):279-290
  8. **Park SS**, Park Y, Yoon S, Lee D, Jeong J, Kim K. Real-world treatment patterns, outcomes, and economic costs by lines of therapy in patients with newly diagnosed multiple myeloma: a nationwide population-based cohort study in South Korea. *Blood Res.* 2025 Apr 15;60(1):26.
-